Co-Diagnostics Soars on Ebola Test Progress; NRx, Novavax Gain

Co-Diagnostics Inc. (CODX) shares surged over 30% on Wednesday, May 27, 2026, leading biotech gainers after the company announced key progress in developing a rapid Ebola virus assay. The stock was among the most actively traded in premarket action, extending a rally that began late Tuesday. NRx Pharmaceuticals Inc. (NRXP) climbed 12% as investors positioned ahead of a Food and Drug Administration decision expected within weeks on its treatment for bipolar depression. Separately, Novavax Inc. (NVAX) rose 4% on anticipation of an upcoming Phase 3 influenza vaccine data readout. The moves came amid a broader uptick in speculative biotech names, with the SPDR S&P Biotech ETF (XBI) up 1.2% on the session. CODX’s assay advancement addresses a critical need for rapid Ebola testing, a market that has drawn increased attention following recent outbreaks in Africa.